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OBJECTIVES: Scintigraphy is generally not the first choice treatment for prostate cancer, although successful studies
using bombesin analog radiopeptides have been performed. Recently, a novel peptide obtained using a phage
display library demonstrated an affinity for prostate tumor cells. The aim of this study was to compare the use of a
bombesin analog to that of a phage display library peptide (DUP-1) radiolabeled with technetium-99m for the
treatment of prostate carcinoma. The peptides were first conjugated to S-acetyl-MAG3 with a 6-carbon spacer,
namely aminohexanoic acid.
METHODS: The technetium-99m labeling required a sodium tartrate buffer. Radiochemical evaluation was
performed using ITLC and was confirmed by high-performance liquid chromatography. The coefficient partition
was determined, and in vitro studies were performed using human prostate tumor cells. Biodistribution was
evaluated in healthy animals at various time points and also in mice bearing tumors.
RESULTS: The radiochemical purity of both radiotracers was greater than 95%. The DUP-1 tracer was more
hydrophilic (log P = -2.41) than the bombesin tracer (log P = -0.39). The biodistribution evaluation confirmed this
hydrophilicity by revealing the greater kidney uptake of DUP-1. The bombesin concentration in the pancreas was
greater than that of DUP-1 due to specific gastrin-releasing peptide receptors. Bombesin internalization occurred
for 78.32% of the total binding in tumor cells. The DUP-1 tracer showed very low binding to tumor cells during the
in vitro evaluation, although tumor uptake for both tracers was similar. The tumors were primarily blocked by DUP-
1 and the bombesin radiotracer primarily targeted the pancreas.
CONCLUSION: Further studies with the radiolabeled DUP-1 peptide are recommended. With further structural
changes, this molecule could become an efficient alternative tracer for prostate tumor diagnosis.
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INTRODUCTION
Many investigations have been conducted using diag-
nostic radiotracers specific for prostate cancer, as prostate
cancer is a condition characterized by substantial morbidity
and mortality. Radiolabeled bombesin analog are preferable
because they target gastrin-releasing peptide receptor
(GRPR)-expressing tumors (1-2). GRPR is highly expressed
on the surface of malignant human prostate cells, and its
specificity for prostate cancer, compared to benign hyper-
plastic prostate tissue, has been demonstrated (3-5).
Bombesin (BBN) is a 14-amino acid neuropeptide that was
isolated from the skin of the European Bombina frog, and it
shows a high affinity for the gastrin-releasing peptide
receptor. BBN and its mammalian homolog, GRP, share a
seven-amino-acid sequence in their C-terminal region, which
is essential for receptor binding and biological activity (6,7).
Most studies that have used radiolabeled BBN have
focused on prostate cancer, although some have also
focused on breast cancer (8,9). Recent efforts in the field of
phage display technology have led to significant drug
discoveries. Phage display peptide libraries encompass
high-affinity molecules that show potential for use in cancer
diagnosis (10).
The synthetic peptide FRPNRAQDYNTN (DUP-1) was
identified by phage display techniques. The DUP-1 peptide
binds to DU-145 prostate cells and also to PC-3 cells with
high affinity (11).
DUP-1 has been radiolabeled with iodine-131 (11) and
also recently with indium-111 (111In) (12). However, no
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reports have focused on the use of one of the most widely
used SPECT radioisotopes, technetium-99m (99mTc).
Askoxilakis et al. (12) demonstrated that the phage
display linear molecule DUP-1 is generally serum-instable,
which suggests the existence of targeted modifications, such
as cyclization, an exchange of amino acids, such D-amino
acids, and peptide acetylation.
Technetium-99m (99mTc) has many advantages, including
its widespread availability, low cost and convenient
physicochemical properties, such as its half-life (t1/2 = 6 h)
and gamma energy (Ec= 140 keV). Moreover, it can also be
provided as part of a ready-to-use lyophilized kit. Different
approaches have been used to label biomolecules with 99mTc
by means of bifunctional chelators, including hydrazine-
nicotinic acid (HYNIC) or mercaptoacetylglycyltriglycine
(MAG3). The use of preformed metallic precursors, such as
organometallic 99mTc(CO)3 or
99mTc-nitrido, as well as the
3+1 or 4+1 mixed ligand approach and the ‘‘click chemistry’’
procedure are additional approaches used for labeling (13).
The S-acetyl NHS-MAG3 chelator was originally used for
the post-conjugation labeling of antibodies, peptides and
oligomers with 99mTc; this is typically performed at a
neutral pH and at room temperature.
The aim of this study was to compare the use of a
bombesin analog to that of a phage display peptide (DUP-1)
labeled with technetium-99m for experimental prostate
carcinoma. PC3 human prostate cancer cells were used in
this study, and these represent an attractive target for
bombesin markers because they overexpress GRPR. Schally
and co-workers have further shown that there are 44,000
bombesin receptor sites/cell on PC-3 human prostate cancer
cells (14).
The peptides were conjugated with S-acetyl mercaptoace-
tyl-triglycine (SAMA-G3) using a six-carbon spacer, namely
aminohexanoic acid (Figs. 1 and 2). It was hypothesized that
both the classic bombesin tracer as well as the DUP-1 tracer
would be confirmed as potential tools for nuclear medicine
diagnoses.
MATERIALS AND METHODS
Materials
All of the chemicals used were reagent-grade (Sigma-
Aldrich and Merck, Sa˜o Paulo, Brazil). The peptide-conjugated
bombesin analog (SAMA-G-G-G-Ahx-QWAVGHLM-NH2,
abbreviated as SAMA-G3-Ahx-BBN) and the phage dis-
play peptide DUP-1 (FRPNRAQDYNTNK-SAMA-G-G-G-
Ahx-NH2, abbreviated as SAMA-G3-Ahx-DUP-1) (Figures 1,
2) were purchased from piChem Laboratory (Graz, Austria).
99mTc, in the form of Na99mTcO4, was eluted in saline from
an alumina-based 99Mo/99mTc generator, which was sup-
plied by the Institute of Energetic and Nuclear Research/
Brazilian Commission of Nuclear Energy (IPEN/CNEN, Sa˜o
Paulo, Brazil). Silica gel strips (ITLC-SG, Gelman Science,
Ann Arbor, MI, USA) were used for instant thin-layer
chromatography. Reverse-phase high-performance liquid
chromatography (RP-HPLC, Shimadzu, Kyoto, Japan) was
also performed using a Symmetry C-18 column (5.0 mm,
100 A˚, 4.66250 mm, Waters, Milford, MA, USA).
Radioactivity measurements were conducted using an
automated, well-typed c-counter NaI(Tl) crystal (Canberra,
Meriden, CT, USA). The PC-3 human prostate adenocarci-
noma cell line was obtained from the American Type
Culture Collection (ATCC, Manassas, VA, USA). Male Swiss
albino mice (20 - 25 g) and male nude mice (16 - 20 g) were
used for the biodistribution studies, and the animals were
provided by the Animal Facility of IPEN/CNEN in Sa˜o
Paulo, Brazil.
Methods
Radiolabeling of conjugated peptides and radiochemical
evaluation. The conjugated peptides (10 mL of a mg/mL
Figure 1 - Structure of conjugated bombesin (SAMA-G-G-G-Ahx-QWAVGHLM-NH2); chemical formula: C59H89N17O15S2; molecular
weight: 1340.57.
Figure 2 - Structure of conjugated DUP-1 (FRPNRAQDYNTNK) (SAMA-G-G-G-Ahx)-NH2; chemical formula: C85H131N29O27S; molecular
weight: 2023.19.
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solution) were labeled with 300 mL of technetium-99m using
sodium tartrate dissolved in a labeling buffer (0.5 M
ammonium bicarbonate, 0.25 M ammonium acetate,
0.18 M ammonium hydroxide, 1:1:1) along with a
stannous chloride solution (chloridric acid/ascorbic acid).
The reaction was induced by heating the mixture to 100 C˚
for 20 min. Radiochemical evaluation was performed using
instant thin-layer chromatography on silica gel strips, and
the mobile phase consisted of methylethylketone (MEK) and
a solution of 50% acetonitrile (ACN).
Each of the radiolabeled conjugates was also character-
ized by reverse-phase high-performance liquid chromato-
graphy analysis. All solvents used in the chromatographic
analyses were HPLC-grade and had been previously filtered
through 0.22-mm membrane filters (Millipore, Milford, MA,
USA).
The HPLC solvents consisted of H2O, which contained
0.1% trifluoroacetic acid (Solvent A), and ACN, which
contained 0.1% trifluoracetic acid (Solvent B). The HPLC
gradient system began with a solvent composition of 95% A
and 5% B, which was followed by a linear gradient of 30% A
and 70% B from 0 to 25 min and 5% A and 95% B from 25 to
30 min.
Determination of log P values. The radiotracers (100 mL)
were dissolved in a mixture of equal volumes (3 mL to
3 mL) of n-octanol and water. After the mixture had been
vigorously stirred and centrifuged, samples (in triplicate)
from both phases (n-octanol and water) were collected and
their radioactivity was measured using a gamma counter.
In vitro cell binding assays. PC3 androgen-independent
human prostate carcinoma cells were cultured in RPMI 1640
medium (Sigma-Aldrich, Sa˜o Paulo, Brazil) that was
supplemented with 10% (v/v) fetal calf serum. The cells
were kept at 37 C˚ in a humidified air environment
containing 5% CO2. They were grown to near confluency
and were then harvested by trypsinization. Cells (106 cells/
well) were seeded into six- and twelve-well culture plates
for the binding studies 24 h before the experiment.
The culture plates were then filled with increasing
concentrations (1 nM to 18 nM) of cold, nonlabeled con-
jugates along with 90 pM of 99mTc-labeled peptide and were
subsequently incubated for 120 min.
Internalization studies were also performed in triplicate at
15, 30, 60, 90, and 120 min time points with and without an
excess of 1 mM cold conjugated peptide for nonspecific
internalization. The supernatant was collected, and cell
surface-bound radioligand was removed with a two-step
acid wash. Internalized radioligand was evaluated by lysing
the cells with 1 M NaOH for 5 min, and radioactivity was
measured with the automated c counter.
In vivo studies. All experiments were carried out in
compliance with the protocol that had been approved by the
local Animal Welfare Committee. Suspensions of PC3 cells
(5.06106) were subcutaneously injected into the upper back
regions of athymic male nude mice. The tumors were
allowed to grow in vivo for 2–3 weeks, at which point the
tumor diameter was approximately 1 cm.
99mTc-conjugated peptides were injected via the tail vein
into healthy Swiss mice (0.1 mL/18.5 MBq), and the
biodistribution was evaluated at 5, 30, 90, and 240 min
post-injection using six mice for each time point. All animals
were sacrificed by cervical dislocation. Subsequently, all
major organs and tissue samples were excised, weighed and
counted with a NaI(Tl) gamma counter, and the percentage
of the injected dose per gram of tissue was calculated using
the activity of the injected dose as a standard.
Biodistribution was analogously evaluated in tumor-bearing
mice at 30 and 90 min post-injection and was followed by
blocking studies, which involved the coinjection of excess
amounts of cold conjugate.
Tumor imaging. Planar imaging studies were performed
with anesthetized mice that were horizontally placed under
the collimator of a Mediso Imaging System (Budapest,
Hungary). A low-energy, high-resolution collimator was
used, and images were acquired at 0.5 h and 1.5 h post-
injection using a 2566256616 matrix size and a 20% energy
window set at 140 keV for a period of 180 s.
Statistical analysis. Quantitative data were expressed as
the mean ¡ SD. Means were compared by an independent
Student’s t test. p-values less than 0.05 were considered
significant.
RESULTS
Both conjugates were radiolabeled using the same
protocol. Radiolabeling with 99mTc was performed via
stannous-tartrate exchange. The radiochemical purities of
99mTc-MAG3-Ahx-BBN and
99mTc-MAG3-Ahx-DUP-1 were
96.3¡0.32% and 96.0¡0.15%, respectively, and the corre-
sponding retention times by HPLC were 12.1 min and
13.4 min, respectively (Figure 3).
The specific activity of 99mTc-MAG3-Ahx-BBN was
148.8 MBq/nM, and that of 99mTc-MAG3-Ahx-DUP-1 was
224.7 MBq/nM.
The lipophilicity of the radiotracers was determined
according to their proportional distribution between octanol
and water. A partition ratio of 0.4065, where log p=
-0.39¡0.02, indicated moderate hydrophilicity for the
99mTc-MAG3-Ahx-BBN. It was more remarkable for
99mTc-
MAG3-Ahx-DUP1, with a partition ratio of 0.00389 and log
p= -2.41¡0.12.
Radioactivity associated with PC3 tumor cells for 99mTc-
BBN tracer was 28.87%. A sharp decrease (93%) of the
binding was observed with increase of the amount of cold
BBN (0 to 18 nM). For 99mTc- SAMA-G3-Ahx-DUP1 the
binding value was much lower, , 1.97%, diminishing by a
factor of 63% at the highest concentration of 18 nM
(Figure 4).
Figure 3 - Reverse-phase HPLC profile: (A) 99mTc-SAMA-G3-Ahx-
BBN; (B) 99mTc- SAMA-G3-Ahx-DUP-1.
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The internalization of the tracers by PC3 cells, as a
function of time for the two radiolabeled peptide deriva-
tives, is illustrated in Figure 5. Internalization was assessed
both in the absence and presence (blocking experiments) of
the native peptides.
The rate of internalization was time-dependent for 99mTc-
SAMA-G3-Ahx-BBN. Incubation at 37 C˚ resulted in an
increased internalization rate, as 20.36¡0.83% of the radio-
activity was internalized at 120 min. The internalization
reached its maximum (78.32%) of total binding by 2 h.
99mTc- SAMA-G3-Ahx-DUP-1, as evaluated under the same
conditions, displayed a much lower rate of internalization,
which was in the range between 5.78% and 9.34% and
remained stable at all time points.
The biodistribution evaluation in healthy animals con-
firmed that kidney uptake was more robust for the DUP
tracer than for the BBN tracer (p , 0.05). Blood depuration
was rapid and similar for both tracers (p . 0.05). Intestinal
uptake was high and also equivalent for both radiotracers (p
. 0.05). Hepatobiliary excretion was predominant for the
BBN tracer, whereas the hepatobiliary system and the
urinary system were found to be the major excretory
pathways for the DUP tracer. 99mTc-SAMA-G3-Ahx-BBN
exhibited greater uptake in the pancreas (p , 0.05) than
99mTc-SAMA-G3-Ahx-DUP-1.
Clearance from the blood and from other GRP receptor-
negative tissues (heart, lung, spleen, stomach, muscle, and
bone) was rapid, as less than 1% ID/g was detected 30 min
after the injection of either radiotracers BBN and DUP-1
(Table 1).
The biodistribution for nude mice bearing PC3 tumors is
shown in Table 2 and Figures 6 and 7. Lung uptake was in
the range of 1% ID/g, and that of the heart, muscle and bone
was less than 1% ID/g. Tumor uptake was not significantly
different for the two radiotracers (p . 0.05).
The excretion profile was also investigated for the tumor-
bearing mice (Figure 6). The highest level of kidney uptake
for 99mTc-SAMA-G3-Ahx-DUP-1 was documented at 30 min
post-injection. No differences occurred (p . 0.05) between
blocked and unblocked animals (Figures 6 and 7).
The liver uptake of 99mTc-SAMA-G3-Ahx-BBN confirmed
that tracer elimination was rapid, as the uptake values at
90 min were significantly decreased.
Figure 4 - Cellular uptake of the radiotracers 99mTc-SAMA-G3-
Ahx-BBN and 99mTc-SAMA-G3-Ahx-DUP-1 in PC-3 human pros-
tate carcinoma cells at 37˚C. Percentage of total binding
radioactivity vs. an increasing concentration of the respective
cold peptide.
Figure 5 - Internalization of the radiotracers: total binding represents uptake on the surface membrane plus that inside of the cell;
internalization represents the activity inside of the cell only. (A) Total binding – 99mTc-SAMA-G3-Ahx-BBN; (B) Internalization – 99mTc-
SAMA-G3-Ahx-BBN; (C) Total binding – 99mTc- SAMA-G3-Ahx-DUP-1; (D) Internalization 99mTc- SAMA-G3-Ahx-DUP-1.
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As shown in Figure 7, as well as in Table 2, the cold
conjugate-blocked tumor uptake values for the BBN tracer
were 32% and 49%, and those for the DUP tracer were 82%
and 83% at 30 and 90 min post-injection, respectively. The
pancreas was 93.19% blocked at 30 min and 97.06% blocked
at 90 min using cold BBN, and these blockage values for the
cold DUP-1 were decreased at 32.53% and 53.85%, respec-
tively DUP-1 (Figure 7).
The scintigraphic images are shown in Figure 8. The
tumor images that were acquired 90 min post-injection
revealed approximately 60% less uptake than at the earlier
time point. High uptake was observed in the gastrointestinal
tract, and the prostate tumor was clearly visualized at
30 min post-injection. Although the image quality was
somewhat better for the BBN tracer, the region of interest
(ROI) measurements for both radiotracers were not sig-
nificantly different (p . 0.05).
DISCUSSION
The radiolabeling of many peptides requires functional
groups, such as spacers, chelators, or radiometals, for
improved conjugation or more favorable kinetics. The
preferred chelators for peptide labeling using technetium
include HYNIC, the tricarbonyl core, and N3S types, such as
benzoyl or S-acetyl-MAG3 (mercaptoacetyl-Gly-Gly-Gly).
The S-acetyl group is reported to remain intact after
conjugation; thus, the risk of subsequent degradation of
the molecule is low (15). Degradation was not measured in
the present circumstance, but it may be a useful parameter
for future studies. The radiolabeling yield in this study
was high, thus precluding the need for radiolabeling
optimization.
Drug transportation characteristics are influenced by the
partition coefficient because this coefficient affects how
drugs reach the target organs and other structures at the site
of action. 99mTc-SAMA-G3-Ahx-DUP-1 was more hydro-
philic than 99mTc-SAMA-G3-Ahx-BBN, and this was con-
firmed by its stronger kidney uptake. This hydophilicity is a
valuable feature of the compound that improved its
solubilization and access to body systems. In the case of
the prostate, too much radioactivity in the urinary system
may interfere with tumor imaging; however, this limitation
can be offset by simultaneous amino acid administration (6).
Table 1 - Biodistribution of the 99mTc conjugates in healthy Swiss mice.
Tissue
%ID/g Time
5 min 30 min 90 min 240 min
BBN* DUP** BBN* DUP** BBN* DUP** BBN* DUP**
Blood 1.64¡0.22 1.21¡0.02 0.36¡0.06 0.43¡0.06 0.12¡0.03 0.08¡0.01 0.05¡0.01 0.05¡0.01
Heart 0.61¡0.20 0.82¡0.14 0.14¡0.05 0.24¡0.07 0.06¡0.01 0.04¡0.01 0.04¡0.02 0.03¡0.02
Lung 1.56¡0.33 1.48¡0.23 0.51¡0.06 0.73¡0.16 0.21¡0.03 0.15¡0.037 0.13¡0.03 0.13¡0.07
Kidney 1.81¡0.06 22.62¡2.03 3.01¡0.78 21.06¡0.41 0.62¡0.01 7.28¡2.07 0.29¡0.03 3.22¡0.43
Spleen 1.45¡0.24 1.37¡0.18 0.64¡0.05 0.28¡0.07 0.29¡0.08 0.09¡0.03 0.73¡0.07 0.07¡0.02
Stomach 1.49¡0.20 0.73¡0.17 0.49¡0.05 0.91¡0.11 0.83¡0.32 0.27¡0.01 0.67¡0.05 0.29¡0.01
Pancreas 6.58¡1.67 1.44¡0.33 2.78¡0.23 0.18¡0.11 1.67¡0.33 0.05¡0.01 0.35¡0.05 0.04¡0.01
Liver 10.05¡2.18 12.31¡2.19 2.79¡0.47 8.58¡1.75 1.58¡0.45 1.57¡0.57 1.54¡0.06 1.53¡0.64
L. Int. 4.17¡0.77 2.92¡0.24 1.00¡0.22 1.11¡0.07 2.00¡1.21 0.33¡0.28 19.40¡0.9 15.45¡2.8
S. Int. 12.03¡3.37 16.57¡3.02 14.34¡2.58 13.31¡4.46 18.17¡2.27 14.62¡2.15 0.38¡0.11 1.43¡0.49
Muscle 0.33¡0.05 0.77¡0.06 0.11¡0.03 0.14¡0.04 0.10¡0.04 0.51¡0.01 0.06¡0.02 0.17¡0.07
Bone 0.51¡0.09 0.84¡0.17 0.13¡0.01 0.20¡0.01 0.11¡0.05 0.05¡0.02 0.40¡0.11 0.05¡0.01
Abbreviations: L. intestine: large intestine; S. Int: small intestine;
(*)99mTc-SAMA-G3-Ahx-BBN; (**)99mTc-SAMA-G3-Ahx-DUP-1.
Data are expressed as the mean ¡ SD (n = 6). The radioactivity in the stomach and intestine was evaluated after thoroughly removing the luminal
contents.
Table 2 - Biodistribution of the 99mTc tracers in Nude mice bearing PC-3 tumors.
Tissue
%ID/g Time post-injection
30 min 90 min
BBN*
BBN*
Block DUP**
DUP**
Block BBN* BBN* Block DUP** DUP** Block
Blood 0.72¡0.15 0.98¡0.29 0.69¡0.14 0.58¡0.16 0.20¡0.06 0.13¡0.03 0.23¡0.06 0.12¡0.02
Heart 0.34¡0.08 0.54¡0.04 0.41¡0.02 0.40¡0.08 0.10¡0.01 0.09¡0.02 0.10¡0.10 0.09¡0.01
Lung 1.20¡0.32 1.40¡0.23 1.24¡0.43 0.98¡0.23 1.05¡0.19 1.02¡0.21 0.34¡0.27 0.29¡0.04
Spleen 1.51¡0.55 1.40¡0.12 0.56¡0.13 0.49¡0.11 0.72¡0.31 0.65¡0.13 0.54¡0.19 0.62¡0.11
Stomach 0.94¡0.27 0.90¡0.20 1.05¡0.07 1.23¡0.34 0.65¡0.22 0.31¡0.06 0.72¡0.27 0.66¡0.16
Muscle 0.27¡0.09 0.30¡0.03 0.27¡0.27 0.23¡0.03 0.25¡0.04 0.16¡0.03 0.31¡0.11 0.28¡0.03
Bone 0.50¡0.12 0.78¡0.13 0.31¡0.08 0.27¡0.02 0.24¡0.08 0.29¡0.02 0.30¡0.05 0.24¡0.02
Tumor 0.75¡0.15 0.51¡0.17 0.85¡0.19 0.15¡0.03 0.29¡0.05 0.16¡0.02 0.41¡0.11 0.07¡0.01
Uptake ratio (tumor/normal tissue)
Tumor/blood 1.04 1.23 1.45 1.78
Tumor/muscle 2.78 3.15 1.16 1.32
(*)99mTc-SAMA-G3-Ahx-BBN; (**)99mTc-SAMA-G3-Ahx-DUP-1. The data are expressed as the mean ¡ SD (n = 6).
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PC3 human prostate cancer cells overexpress gastrin-
releasing peptide receptor (GRPR), which renders them an
attractive target for bombesin markers. Schally and co-
workers have shown that there are 44,000 bombesin
receptor sites/cell on PC-3 human prostate cancer cells (16).
Zitzmann et al. (11) used a 12-mer M13 phage display
peptide library to screen for ligands of the DU-145 prostate
carcinoma cell line, as well as those of PC3 cells. After six
rounds of biopanning, all sequenced phage clones were
found to display the same peptide, FRPNRAQDYNTN
(DUP-1). The number of cell receptors for this molecule has
not been estimated. Nevertheless, the Zitzman group (11)
validated the binding of DUP-1 to PC-3 cells using a
radioactive derivative of DUP-1 in the presence of increas-
ing concentrations of unlabeled DUP-1 (17).
Cell binding assays in the current study were consistent
with the higher affinity of the BBN tracer. For DUP-1,
maximum binding and internalization were reached after
5 min and subsequently decreased over time. A comparable
profile of cell binding and internalization has been
described for 131I-DUP-1 regarding DU-145 and PC3 tumor
cells (11).
Such differences between BBN and DUP-1 may be
partially explained by the fact that the DUP-1 conjugate
has twice the molecular weight and a greater hydrophilicity
than BBN. Degradation was not considered to be a problem
in this study, as higher rather than lower blood concentra-
tions tend to occur in such circumstances. The BBN
concentration in the pancreas was also significantly greater,
which is in accordance with the literature. The pancreas has
Figure 6 - Excretion organ uptake of 99mTc- peptides in urethane-anesthetized mice (0.1 mL/18.5 MBq).
Figure 7 - Pancreatic and tumor uptake in regular, as well as blocked, urethane-anesthetized animals (0.1 mL/18.5 MBq): (A) 99mTc-
SAMA-G3-Ahx-BBN 30 min; (B) 99mTc-SAMA-G3-Ahx-BBN 90 min; (C) 99mTc-SAMA-G3-Ahx-DUP 30 min; (D) 99mTc-SAMA-G3-Ahx-DUP
90 min.
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long been known to express a large number of GRP
receptors (18). Indeed, this number is approximately
eightfold greater than that of PC3 tumors (18). These
properties of BBN suggest that this peptide will likely
remain the first choice for prostate cancer, although this
does not rule out interest in alternative agents.
The chosen time (30 min) for the evaluation of the tumor-
bearing mice was based on blood clearance. Blood elimina-
tion was conveniently rapid and demonstrated an uptake of
less than 0.5% ID/mL. However, the optimal time for the
BBN diagnosis was 90 min post-injection. Our preliminary
conjugation of the molecule probably improved its stability,
compared to the study of Zitzmann et al. (11) that
demonstrated decreased blood uptake.
DUP-1 evaluation times for the tumors were less ideal.
The highest cell binding values occurred as early as 5 min
after incubation. By 30 min, the DUP-1 tracer, which has
been shown to bind very quickly, may have already been
washed out. Also, Askoxylakis et al. (12) observed
elevated 131I-DUP tumor uptake at the relatively early
time of 15 min. Thus, future studies should begin assess-
ments at earlier time-points to disclose stronger cell
affinities and higher concentrations than were reported
here. In addition, binding affinity was reduced in the
study by Askoxylakis et al., which evidenced the difficul-
ties associated with reaching an ideal molecular design.
These authors concluded that the sequence in the middle
of the NRAQDY molecule may be significant for target
binding.
The occurrence of instability and degradation was
suggested by Askoxylakis et al., but this was not in
agreement with the findings of others. Phage display
peptides have been used as vehicles for the delivery of
drugs and other biomolecules, and they have achieved high
success due to their affinity and selectivity for a variety of
cellular targets. Attention to peptide conformation and the
chemical synthesis of specific molecules have been cited as
the greatest potential challenges for this technique (19,20).
As a result, stability studies were not considered a priority
in the current investigation.
Functional groups are crucial for the optimization of
peptide tracers, and this also applies to DUP-1. Accordingly,
the glycosylation state of the peptide and the effects of
various chelators need to be assessed by future studies.
Both the BBN and DUP-1 tracers exhibited low but
consistent tumor uptake. The DUP-1 tumor uptake values
likely experienced interference due to the experimental
design, as peak values were missed at the comparatively
long analysis interval of 30 min. Improvements in the
design of the molecule, which may result in more favorable
pharmacokinetics, along with the use of a shorter assess-
ment timeframe may substantially enhance the potential of
DUP-1 to be used as a prostate tumor radiopeptide.
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